1. Research Methodology
2.Executive Summary
3.Strategic Recommendations
3.1 APAC region to witness augmented growth in the forecast period
3.2 Evolution of CT-FFR technology in the forthcoming period
4. Oral Anti-iDabetic Drugs Market: Product Outlook
5. Global Oral Anti-diabetic drug Market : Growth and Forecast
5.1 By Value (2014-2018)
Table 1: Global Oral Anti-diabetic drug Market Size, By Value, 2014-2018 (USD Million)
5.2By Value (2019-2024)
Table 2: Global Oral Anti-diabetic drug Market Size, By Value, Forecast, 2019-2024 (USD Million)
Table 3: Worldwide Diabetes Prevalence
Table 4: Prescribed diabetes medications globally
Table 5: Drug spending pattern, By top 10 therapy classes, In 2018
Table 6 : Population ages 65 and above, By Select Region, 2013-2017 (% of total)
Table 7: Projected global population aged 60 years & above (In Billions)
Table 8: Projected global population (In Billions)
Table 9: Undiagnosed cases of diabetes (20-79 years), By Region, In 2017
Table 10: Top 10 countries with diabetic population along with their healthcare expenditure, In 2017, In Million
Table 11: Deaths attributable to diabetes, In 2017
Table 12: Total healthcare expenditure and mean healthcare expenditure per person and per income group, In 2017Table 16: Global Oral Anti-diabetic drug Market Size, By Type, 2024 (In %)
6. Global Oral Anti-Diabetic Drugs Market: Segment Analysis
6.1 Global Oral Anti-diabetic drug Market Size, By Type: Breakdown (%)
Table 13: Global Oral Anti-diabetic drug Market Size, By Type, 2018 (%)
Table 14: Global Oral Anti-diabetic drug Market Size, By Type, 2024F (%)
6.1.1 Global Oral Anti-diabetic drug Market Size, By Type, 2018 (%)
Table 15: Global Oral Anti-diabetic drug Market Size, By Type, 2018 (In %)
6.1.2 Global Oral Anti-diabetic drug Market Size, By Type, 2024 (%)
Table 16: Global Oral Anti-diabetic drug Market Size, By Type, 2024 (In %)
6.2 Global Biguanides Oral Anti-diabetic drug Market, By Value (2014-2024)
Table 17: Global Biguanides Oral Anti-diabetic drug Market, By Value, 2014-2018 (USD Million)
Table 18: Global Biguanides Oral Anti-diabetic drug Market, By Value, Forecast, 2019-2024(USD Million)
6.3 Global Sulfonylureas Oral Anti-diabetic drug Market, By Value (2014-2024)
Table 19: Global Sulfonylurease Oral Anti-diabetic drug Market, By Value, 2014-2018 (USD Million)
Table 20: Global Sulfonylurease Oral Anti-diabetic drug Market, By Value, Forecast, 2019-2024(USD Million)
6.4 Global Thiazolidinediones Oral Anti-diabetic drug Market, By Value (2014-2024)
Table 21 : Global TZDs Oral Anti-diabetic drug Market, By Value, 2014-2018 (USD Million)
Table 22: Global TZDs Oral Anti-diabetic drug Market, By Value, Forecast, 2019-2024(USD Million)
6.5 Global Alpha- glucosidase inhibitors Oral Anti-diabetic drug Market, By Value (2014-2024)
Table 23: Global ? Glucosidase Inhibitors Oral Anti-diabetic drug Market, By Value, 2014-2018 (USD Million)
Table 24: Global ? Glucosidase Inhibitors Oral Anti-diabetic drug Market, By Value, Forecast, 2019-2024(USD Million)
6.6 Global Dipeptidyl peptidase IV inhibitor Oral Anti-diabetic drug Market, By Value (2014-2024)
Table 25: Global DPP-4 Inhibitors Oral Anti-diabetic drug Market, By Value, 2014-2018 (USD Million)
Table 26: Global DPP-4 Inhibitors Oral Anti-diabetic drug Market, By Value, Forecast, 2019-2024(USD Million)
6.7 Global Sodium Glucose Co- transporter-2 inhibitor Oral Anti-diabetic drug Market, By Value (2014-2024)
Table 27: Global SGL2 Inhibitors Oral Anti-diabetic drug Market, By Value, 2014-2018 (USD Million)
Table 28: Global SGL2 Inhibitors Oral Anti-diabetic drug Market, By Value, Forecast, 2019-2024(USD Million)
6.8 Global Others Oral Anti-diabetic drug Market, By Value (2014-2024)
Table 29: Global Others Oral Anti-diabetic drug Market, By Value, 2014-2018 (USD Million)
Table 30: Global Others Oral Anti-diabetic drug Market, By Value, Forecast, 2019-2024(USD Million)
6.9 Global Oral Anti-diabetic drug Market: Market Attractiveness, By Type
Table 31: Market Opportunity Chart of global Oral Anti-diabetic drug Market - By Type, By Value (Year - 2024)
7. Global Oral Anti-diabetic Drug Market: Regional Analysis
7.1 Global Oral Anti-diabetic drug Market Size, By Region : Breakdown (%)
Table 32: Global Healthcare Landscape, By Select Region
7.1.1 Global Oral Anti-diabetic drug Market Size, By Region, 2018 (%)
Table 33: Global Oral Anti-diabetic drug Market Size, By Region, 2018 (%)
7.1.2 Global Oral Anti-diabetic drug Market Size, By Region, 2024 (%)
Table 34 : Global Oral Anti-diabetic drug Market Size, By Region, 2024 (%)
7.2 North America Oral Anti-diabetic drug Market: Growth and Forecast
7.2.1 By Value (2014-2018)
Table 35: North America Oral Anti-diabetic drug Market Size, By Value, 2014-2018 (USD Million)
7.2.2 By Value (2019-2024)
Table 36 : North America Oral Anti-diabetic drug Market Size, By Value, Forecast, 2019-2024 (USD Million)
Table 37 : Prevalence of diabetes in North America, By age and sex, In 2017
Table 38 : Prevailing diabetes trend in North America
Table 39 : Top 5 countries with diabetic patients in North America and Caribbean Region, In 2017
Table 40: North America population aged 65 and above, 2013-2018 (% of total)
Table 41: Prevalence of Diabetes in North America, 2017 & 2045E (In Million)
Table 42: North America GDP, 2012-2017 (USD Trillion)
Table 43 : North America GDP per capita, current prices, 2013-2023F (In USD)
7.2.3 North America Oral Anti-diabetic drug Market: Major Market Players
Table 44: Competitive Positions of Select Companies Operating in North America Oral Anti-diabetic drug Market (2018)
7.2.4 By Type, By Value (2014-2018)
Table 45: North America Oral Anti-diabetic drug Market: By Type, By Value, 2014-2018 (USD Million)
7.2.5 By Type, By Value (2019-2024)
Table 46: North America Oral Anti-diabetic drug Market: By Type, By Value, 2019-2024 (USD Million)
7.3 North America Oral Anti-diabetic drug Market: Country Analysis (U.S and Canada)
Table 47: North America Oral Anti-diabetic drug Market Size, By Country, 2018 (%)
Table 48: North America Oral Anti-diabetic drug Market Size, By Country, 2024F (%)
7.4 Market Attractiveness of North America Oral Anti-diabetic drug Market By Country
Table 49: Market Opportunity Chart of North America Oral Anti-diabetic drug Market - By Type, By Value (Year - 2024)
7.4.1 U.S Oral Anti-diabetic drug Market, By Value (2014-2024)
Table 50: USA Oral Anti-diabetic drug Market, By Value, 2014-2018 (USD Million)
Table 51: USA Oral Anti-diabetic drug Market, By Value, 2019-2024(USD Million)
Table A: Most common oral anti- diabetic drugs prescribed in United States
Table B: Prescription drugs insurance coverage provided by Medicare Part D in United States
Table 52: U.S., Per Capita Expenditure on Healthcare, 2012-2018 (In USD)
Table 53: Prevalence of diabetes in United States, 2013-2017, In million
Table 54 : U.S., Percentage of diabetic patients afflicted from other consequences as of 2017 (in %)
Table 55: U.S., GDP (Current USD), 2013-2017 (In USD Trillion)
Table 56: U.S., Population ages 65 and above, 2013-2017 (% of total)
Table 57: U.S., Population ages 65 and above, Forecast (In Millions)
7.4.2 U.S Oral Anti-diabetic drug Market, By Type, By Value (2014-2018)
Table 58: U.S. Oral Anti-diabetic drug Market: By Type, By Value, 2014-2018 (USD Million)
7.4.3 U.S Oral Anti-diabetic drug Market, By Type, By Value (2019-2024)
Table 59: U.S. Oral Anti-diabetic drug Market: By Type, By Value, 2019-2024 (USD Million)
7.4.4 Canada Oral Anti-Diabetic Drugs Market, By Value (2014-2024)
Table 60: Canada Oral Anti-diabetic drug Market, By Value, 2014-2018 (USD Million)
Table 61: Canada Oral Anti-diabetic drug Market, By Value, 2019-2024(USD Million)
Table C: Prescription drug coverage plans in Canada
Table D: Most common oral anti- diabetic drugs prescribed in Canada
Table E: Combinational oral anti- diabetic drugs prescribed in Canada
Table 62: Prevalence of diabetes in Canada, 2013-2017,In million
Table 63: Health insurance coverage plans for diabetic patients
Table 64 : Prevalence of Diabetics in Canada, (% of Total Population) 2015 & 2045E
Table 65: Estimated Prevalence of Pre-Diabetics in Canada, (% of Total Population) 2015 & 2045E
Table 66: Overweight and Obese Population in Canada, 2015-2017 (% of total)
Table 67: Canada, Expenditure on Health as a share of GDP, 2012-2017 (In %)
Table 68: Canada, Per Capita Healthcare Expenditure, Table 69: Canada, Population ages 65 and above, 2012-2018 (% of total)2012-2017 (USD)
7.4.5Canada Oral Anti-diabetic drug Market, By Type, By Value (2014-2018)
Table 70: Canada Oral Anti-diabetic drug Market: By Type, By Value, 2014-2018 (USD Million)
Table 71: Canada Oral Anti-diabetic drug Market: By Type, By Value, 2019-2024 (USD Million)
7.4.6 Canada Oral Anti-diabetic drug Market, By Type, By Value (2019-2024)
7.5 Europe Oral Anti-Diabetic Drugs Market: Growth and Forecast
7.5.1 By Value (2014-2018)
Table 72: Europe Oral Anti-diabetic drug Market Size, By Value, 2014-2018 (USD Million)
7.5.2 By Value (2019-2024)
Table 73 : Europe Oral Anti-diabetic drug Market Size, By Value, Forecast, 2019-2024 (USD Million)
Table F: Reimbursement criteria for prescription drugs in Europe
Table 74: Prevalence of Diabetes (Age 18+), 2017 & 2045E (In Million)
Table 75: Diabetes Prevalence (% of population ages 20 to 79), By Select Country, 2017
Table 76: Prevalence of Diabetes Among Children, 2017
Table 77: Obesity Rate, By Select Country, 2017 (In Percentage)
Table 78: European Union, Population ages 65 and above, 2013-2018 (% of total)
Table 79: Per Capita Health Expenditure, By Select Country, 2018 (USD)
Table 80: European Country Population Aged 65 and Above, 2012-2017 (% of Total)
Table 81: GDP, Europe Region, By Select Country, 2017 (In Trillion USD)
7.5.3 Europe Oral AAnti-Diabetic Drugs Market: Major Market players
Table 82: Competitive Positions of Select Companies Operating in Europe Oral Anti-diabetic drug Market (2018)
7.5.4 By Type, By Value (2014-2018)
Table 83: Europe Oral Anti-diabetic drug Market: By Type, By Value, 2014-2018 (USD Million)
7.5.5By Type, By Value (2019-2024)
Table 84: Europe Oral Anti-diabetic drug Market: By Type, By Value, 2019-2024 (USD Million)
7.6Europe Oral Anti-diabetic drug Market: Country Analysis (U.K and Germany)
Table 85:Europe Oral Anti-diabetic drug Market Size, By Country, 2018 (%)
Table 86:Europe Oral Anti-diabetic drug Market Size, By Country, 2024F (%)
7.7 Market Attractiveness of Europe Oral Anti-diabetic drug Market By Country
Table 87: Market Opportunity Chart of Europe Oral Anti-diabetic drug Market - By Type, By Value (Year - 2024)
7.7.1 U.K Oral Anti-Diabetic Drugs Market, By Value (2014-2024)
Table 88: U.K. Oral Anti-diabetic drug Market, By Value, 2014-2018 (USD Million)
Table 89: U.K. Oral Anti-diabetic drug Market, By Value, 2019-2024(USD Million)
Table 90: U.K, Pharmaceutical R&D Spending, Euro Million, 2013-2016
Table G: Most common oral anti- diabetic drugs prescribed in United Kingdom
Table H: U.K. employees co-payment plan for prescription drugs at local pharmacies
Table 91: Number of deaths in United Kingdom by diabetes, By sex and age, In 2017
Table I: Prevalence of diabetes and related risk factors in United Kingdom
Table 92: U.K, Health Expenditure Per Capita, PPP, 2012-2017 (USD)
Table 93: U.K, Population Ages 65 and Above (% of total), 2012-2018
Table 94: Prevalence of diabetes in United Kingdom, 2013-2017, In million
7.7.2U.K Oral Anti-diabetic drug Market, By Type, By Value (2014-2018)
Table 95: U.K. Oral Anti-diabetic drug Market: By Type, By Value, 2014-2018 (USD Million)
7.7.3U.K Oral Anti-diabetic drug Market, By Type, By Value (2019-2024)
Table 96: U.K. Oral Anti-diabetic drug Market: By Type, By Value, 2019-2024 (USD Million)
7.7.4 Germany Oral Anti-Diabetic Drugs Market, By Value (2014-2024)
Table 97: Germany Oral Anti-diabetic drug Market, By Value, 2014-2018 (USD Million)
Table 98: Germany Oral Anti-diabetic drug Market, By Value, 2019-2024(USD Million)
Table 99 : German Pharmaceutical companies expenditure on R&D, In Million Euros
Table J: Germany, Healthcare Related Statistics, 2017
Table K: Top 5 countries with number of diabetic people across Europe, In million, In 2017
Table 100: Healthcare spending pattern in Germany, In 2018, In USD $
Table 101: Health insurance coverage in Germany, In 2018
Table 102 : Germany, Health Expenditure Per Capita, PPP, 2012-2017 (USD)
Table 103: Germany, Population ages 65 and above, 2012-2018 (% total)
7.7.5 Germany Oral Anti-diabetic drug Market, By Type, By Value (2014-2018)
Table 104: Germany Oral Anti-diabetic drug Market: By Type, By Value, 2014-2018 (USD Million)
7.7.6 Germany Oral Anti-diabetic drug Market, By Type, By Value (2019-2024)
Table 105: Germany Oral Anti-diabetic drug Market: By Type, By Value, 2019-2024 (USD Million)
7.7.7 France Oral Anti-diabetic drug Market, By Value (2014-2024)
Table 106: France Oral Anti-diabetic drug Market, By Value, 2014-2018 (USD Million)
Table 107: France Oral Anti-diabetic drug Market, By Value, 2019-2024(USD Million)
Table 108: Prevalence of diabetes in France, 2013-2017, In million
Table 109: Prevalence of diabetes and related risk factors in France, In 2017
Table 110: France, Population Ages 65 and Above (% of total), 2012-2018
Table 111: France, Spending on Healthcare, 2015 & 2040,Table 112: Healthcare expenditure in France ( as a % of GDP)
Table 113: Healthcare spending pattern in France, In 2016 & 2050, In USD $(USD Per Person)
7.7.8 France Oral Anti-diabetic drug Market, By Type, By Value (2014-2018)
Table 114: France Oral Anti-diabetic drug Market: By Type, By Value, 2014-2018 (USD Million)
7.7.9 France Oral Anti-diabetic drug Market, By Type, By Value (2019-2024)
Table 115: France Oral Anti-diabetic drug Market: By Type, By Value, 2019-2024 (USD Million)
7.7.10 Italy Oral Anti-diabetic drug Market, By Value (2014-2024)
Table 116: Italy Oral Anti-diabetic drug Market, By Value, 2014-2018 (USD Million)
Table 117: Italy Oral Anti-diabetic drug Market, By Value, 2019-2024(USD Million)
Table 118: Italy, Health Expenditure, (% of GDP), 2013-2017 (USD)
Table 119: Prevalence of diabetes in Italy, 2013-2017,In million
Table 120: Italy, Spending on Healthcare, 2015 & 2040, (USD Per Person)
Table 121: Italy, Population Ages 65 and Above (% of total), 2012-2018
7.7.11 Italy Oral Anti-diabetic drug Market, By Type, By Value (2014-2018)
Table 122: Italy Oral Anti-diabetic drug Market: By Type, By Value, 2014-2018 (USD Million)
7.7.12 Italy Oral Anti-diabetic drug Market, By Type, By Value (2019-2024)
Table 123: Italy Oral Anti-diabetic drug Market: By Type, By Value, 2019-2024 (USD Million)
7.8 APAC Oral Anti-Diabetic Drugs Market: Growth and Forecast
7.8.1 By Value (2014-2018)
Table 124: APAC Oral Anti-diabetic drug Market Size, By Value, 2014-2018 (USD Million)
7.8.2 By Value (2019-2024)
Table 125: APAC Oral Anti-diabetic drug Market Size, By Value, Forecast, 2019-2024 (USD Million)
Table 126: Population ages 65 and above, APAC Region, By Select Countries, 2018 (% of total)
Table 127: Population ages 65 and above, APAC Region, By Select Countries, 2050 (% of total)
Table 128: APAC, GDP, By Select Country, 2017 (In USD Trillion)
Table 129: Diabetes Prevalence (% of population ages 20 to 79), By Select Country, 2018
Table 130 : Obesity Rate, By Select Country, 2017 (In Percentage)
Table L: Global Access to Healthcare Index, Ranking of Select Countries in Asia Pacific Region, 2017 (score out of 10)
7.8.3 APAC Oral Anti-diabetic drug Market: Major Market Players
Table 131: Competitive Positions of Select Companies Operating in Asia Pacific Oral Anti-diabetic drug Market (2018)
7.8.4 By Type, By Value (2014-2018)
Table 132: APAC Oral Anti-diabetic drug Market: By Type, By Value, 2014-2018 (USD Million)
7.8.5 By Type, By Value (2019-2024)
Table 133: APAC Oral Anti-diabetic drug Market: By Type, By Value, 2019-2024 (USD Million)
7.9 APAC Oral Anti-Diabetic Drugs Market: Country Analysis (Japan, India and China)
Table 134: APAC Oral Anti-diabetic drug Market Size, By Country, 2018 (%)
Table 135: APAC Oral Anti-diabetic drug Market Size, By Country, 2024F (%)
7.10 Market Attractiveness of APAC Oral Anti-diabetic drug Market By Country
Table 136: Market Opportunity Chart of APAC Oral Anti-diabetic drug Market - By Type, By Value (Year - 2024)
7.10.1 India Oral Anti-Diabetic Drugs Market, By Value (2014-2024)
Table 137: India Oral Anti-diabetic drug Market, By Value, 2014-2018 (USD Million)
Table 138: India Oral Anti-diabetic drug Market, By Value, 2019-2024 (USD Million)
Table M: Drivers driving Indian Pharmaceutical industry
Table 139: Prevalence of diabetes in India, In million
Table N: Diabetes medications in Indias National List of Essential medicines
Table 140: India, Population ages 65 and above, 2013-2018, In Million
Table 141: India, Share of Urban Population, 2012-2018 (In %)
Table 142: India, GDP Growth Per Year, 2015-2019 (In %)
Table 143: India, Total Population, 2013-2023F (In Million)
7.10.2 India Oral Anti-diabetic drug Market, By Type, By Value (2014-2018)
Table 144: India Oral Anti-diabetic drug Market: By Type, By Value, 2014-2018 (USD Million)
7.10.3 India Oral Anti-diabetic drug Market, By Type, By Value (2019-2024)
Table 145: India Oral Anti-diabetic drug Market: By Type, By Value, 2019-2024 (USD Million)
7.10.4 Japan Oral Anti-Diabetic Drugs Market, By Value (2014-2024)
Table 146: Japan Oral Anti-diabetic drug Market, By Value, 2014-2018 (USD Million)
Table 147: Japan Oral Anti-diabetic drug Market, By Value, 2019-2024 (USD Million)
Table 148: Prevalence of diabetes in Japan, In million
Table 149:Japan Healthcare Expenditure Outlook (2017) (%)
Table 150:Japan, GDP Growth Per Year, 2015-2019F (In %)
Table 151:Japan, Population ages 65 and above, 2012-2017 (% of total)
7.10.5 Japan Oral Anti-diabetic drug Market, By Type, By Value (2014-2018)
Table 152:Japan Oral Anti-diabetic drug Market: By Type, By Value, 2014-2018 (USD Million)
7.10.6 Japan Oral Anti-diabetic drug Market, By Type, By Value (2019-2024)
Table 153:Japan Oral Anti-diabetic drug Market: By Type, By Value, 2019-2024 (USD Million)
7.10.7 China Oral Anti-Diabetic Drugs Market, By Value (2014-2024)
Table 154:China Oral Anti-diabetic drug Market, By Value, 2014-2018 (USD Million)
Table 155:China Oral Anti-diabetic drug Market, By Value, 2019-2024(USD Million)
Table 156:China, Population ages 65 and above, 2012-2018 (% of total)
Table 157:China Healthcare Expenditure Outlook (2018) (%)
Table 158:Prevalence of diabetes in China, In million
Table 159:China, Share of Urban Population, 2012-2018 (In %)
Table 160:China, GDP Growth Per Year, 2015-2019 (In %)
Table 161: China, Total Population, 2013-2021F (In Million)
7.10.8 China Oral Anti-diabetic drug Market, By Type, By Value (2014-2018)
Table 162:China Oral Anti-diabetic drug Market: By Type, By Value, 2014-2018 (USD Million)
7.10.9 China Oral Anti-diabetic drug Market, By Type, By Value (2019-2024)
Table 163:China Oral Anti-diabetic drug Market: By Type, By Value, 2019-2024 (USD Million)
7.11 ROW Oral Anti-diabetic drug Market: Growth and Forecast
7.11.1 By Value (2014-2018)
Table 164:ROW Oral Anti-diabetic drug Market Size, By Value, 2014-2018 (USD Million)
7.11.2 By Value (2019-2024)
Table 165:ROW Oral Anti-diabetic drug Market Size, By Value, Forecast, 2019-2024 (USD Million)
Table 166:Population ages 65 and above, By Select Country, 2017 (% of total)
Table 167:Population ages 60 and above, By Select Country, 2050 (% of total)
Table 168:Latin America and Caribbean, Population ages 65 and above 2012-2018 (% of total)
Table 169:Latin America and Caribbean, Share of Urban Population in Total Population, 2012-2018
Table 170:Middle East and North Africa, Population ages 65 and above (% of total)
Table 171:Middle East and North Africa, GDP, 2012-2018 (In USD Trillion)
Table 172:Prevalence of diabetes in Latin America ad Caribbean, In million
Table 173:Prevalence of diabetes in Middle East and North Africa, In million
Table O:Healthcare expenditure pattern in Middle East and North Africa, In 2017
Table P: Pharmaceutical expenditure in relation to healthcare expenditure in Middle East and North Africa, In 2017
7.11.3 By Type, By Value (2014-2018)
Table 174:ROW Oral Anti-diabetic drug Market: By Type, By Value, 2014-2018 (USD Million)
7.11.4 By Type, By Value (2019-2024)
Table 175:ROW Oral Anti-diabetic drug Market: By Type, By Value, 2019-2024 (USD Million)
7.12 ROW Oral Anti-Diabetic Drugs Market: Country Analysis (Brazil)
Table 176:ROW Oral Anti-diabetic drug Market Size, By Country, 2018 (%)
Table 177: ROW Oral Anti-diabetic drug Market Size, By Country, 2024F (%)
7.12.1 Brazil Oral Anti-Diabetic Drugs Market, By Value (2014-2024)
Table 178: Brazil Oral Anti-diabetic drug Market, By Value, 2014-2018 (USD Million)
Table 179: Brazil Oral Anti-diabetic drug Market, By Value, 2019-2024(USD Million)
Table Q: Healthcare spending pattern in Brazil (In USD)
Table 180:Brazil, Population ages 65 and above, 2012-18 (% of total)
Table 181:Brazil, GDP, 2012-2018 (In USD Trillion)
Table 182:Prevalence of diabetes in Brazil, In million
Table 183:Brazil health expenditure as a share of GDP, 2018
7.14.2 Brazil Oral Anti-diabetic drug Market, By Type, By Value (2014-2018)
Table 184:Brazil Oral Anti-diabetic drug Market: By Type, By Value, 2014-2018 (USD Million)
7.14.3 Brazil Oral Anti-diabetic drug Market, By Type, By Value (2019-2024)
Table 185:Brazil Oral Anti-diabetic drug Market: By Type, By Value, 2019-2024 (USD Million)
8. Global Anti-diabetic drug: Competitive Landscape
8.1 Company Share Analysis
Table 186: Global Leading companies Market Share, By Select Company, 2018 (In %)
8.2 Drugs Analysis
Table 187: Growth of non generic oral diabetic drugs
9.Global Oral Anti-Diabetic Drugs Market Dynamics
9.1 Global Oral Anti-diabetic drug Market Drivers
9.2 Global Oral Anti-diabetic drug Market Restraints
9.3 Global Oral Anti-diabetic drug Market Trends
9.4 Porter Five Force Analysis
9.5 SWOT Analysis
9.6 Policy and Regulatory Landscape
10.Company Profiles
10.1 Novartis
Table 188:Novartis, Net Sales, 2015-2018 (In Billion USD)
Table 189:Galvus, Net Sales, 2014-2018 (In Billion USD)
Table 190:Novartis, Sales, By Innovative Medicine Segment, FY ended March 2018 (%)
Table 191:Novartis, Sales, By Innovative Medicine Segment, FY ended March 2018 (%)
10.2 Pfizer
Table 192:Pfizer, Sales Revenue, 2014-2018 (USD million)
Table 193: Pfizer, Sales, By Business Segment, FY ended March 2018 (In %)
Table 194:Pfizer, By Geographic Region, FY ended March 2017 (In %)
10.3 Sanofi
Table 195:Sanofi Annual Sales Revenue of Cardiac and Vascular Group,2014-2018 (USD Million)
Table 196:Sanofi , Sales, By Business Segment, FY ended March 2018 (%)
Table 197:Sanofi, By Region, FY ended March 2018 (%)
Table 198: Sanofi Annual Sales Revenue of Amaryl ,2014-2018 (USD Million)
Table 199:Sanofi, Amaryl Sales, By Region, FY ended March 2018 (%)
10.4 Takeda Pharmaceuticals
Table 200:Takeda, Net Sales, 2014-2018 (In Million USD)
Table 201:Nesina, Net Sales, 2014-2018 (In Million USD)
Table 202:Takeda, Net Sales, By Geographic Region, 2018 (In %)
Table 203:Nesina, Net Sales, By Geographic Region, 2018 (In %)
10.5 Merck & Co.
Table 204:Merck & Co., Net Sales, 2014-2018 (In Billion USD)
Table 205:Januvia, Net Sales, 2014-2018 (In Billion USD)
Table 206:Janumet, Net Sales, 2014-2018 (In Billion USD)
Table 207:Januvia, Net Sales, By Geographic Region, 2018 (In %)
Table 208:Janumet, Net Sales, By Geographic Region, 2018 (In %)
10.6 AstraZeneca
Table 209: Farxiga, Net Sales, 2014-2018 (In Million USD)
Table 210:Onglyza, Net Sales, 2014-2018 (In Million USD)
Table 211:Farxiga, Net Sales, By Geographic Region, 2018 (In %)
Table 212:Onglyza, Net Sales, By Geographic Region, 2018 (In %)
10.7 Janssen Pharmaceutical
Table 213:Janssen Pharmaceutical, Cardiovascular segment, Net Sales, 2014-2018 (In Million USD)
Table 214:Invokana, Net Sales, 2014-2018 (In Million USD)
Table 215:Cardiovascular segment, Net Sales, By Geographic Region, 2018 (In %)
Table 216:Invokana, Net Sales, By Geographic Region, 2018 (In %)
10.8 Boehringer Ingelheim
Table 217:Jardiance, Net Sales, 2017-2018 (In Million USD)
Table 218:Trajenta, Net Sales, 2017-2018 (In Million USD)
10.9 Eli Lilly
Table 219:Jardiance, Net Sales, 2016-2018 (In Million USD)
Table 220:Trajenta & Jentadueto, Net Sales, 2014-2018 (In Million USD)
Table 221:Jardinace, Net Sales, By Geographic Region, 2018 (In %)
Table 222:Trajenta & Jentadueto, Net Sales, By Geographic Region, 2018 (In %)